Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections.

@article{Sharif2005OcularHD,
  title={Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections.},
  author={N. Sharif and T. Davis and Gary W. Williams},
  journal={Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics},
  year={2005},
  volume={21 2},
  pages={
          121-32
        }
}
  • N. Sharif, T. Davis, Gary W. Williams
  • Published 2005
  • Chemistry, Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
The aim of this study was to define the localization and pharmacology of DP-prostaglandin receptors in human eye sections using a novel DP-antagonist radioligand ([3H]-BWA868C), using various intraocular pressure (IOP)-lowering DP-prostaglandins and the technique of quantitative autoradiography on 20-microm sections of frozen human eyes. [3H]BWA868C yielded well-defined autoradiograms of DP-receptors in human eyes with up to 82% specific binding. High densities of DP-receptors were associated… Expand
ATP-induced relaxation of porcine retinal arterioles in vitro depends on prostaglandin E synthesized in the perivascular retinal tissue.
TLDR
ATP-induced vasodilation depends on the production of PGE in the perivascular retina, however, the regulation of retinal arteriolar tone involves COX products other than PGE. Expand
Prostaglandin analogues: current treatment option for glaucoma
Glaucoma is a progressive optic neuropathy and is the world’s second leading cause of blindness. It is a multifactorial disease that is etiologically complex where elevated intraocular pressure inExpand
Choroidal involution is a key component of oxygen-induced retinopathy.
TLDR
It is demonstrated for the first time pronounced, sustained choroidal vascular involution during the development of ROP, and foundings suggest that effective therapeutic strategies to counter ROP should consider choroid preservation. Expand
Medical Therapy for Glaucoma: The Next 20 Years
TLDR
The next 20 years will see the development of new treatment strategies with longer duration of effect and increased efficacy that will decrease the role of the patient in the treatment equation and reduce adverse events. Expand
Dual effect of prostaglandins on isolated intraocular porcine ciliary arteries
TLDR
Prostaglandin analogues are used to reduce the intraocular pressure in glaucoma, but also affect the tone of the arteries supplying the ciliary body, and the effect on intraocular ciliary arteries is studied. Expand
Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.
  • N. Sharif
  • Medicine
  • ACS pharmacology & translational science
  • 2020
TLDR
The collective efforts of many researchers whose industrious, diligent, and dedicated team work resulted in the discovery, biochemical/pharmacological characterization, development and eventual launch of drugs to treat AC, and for treating ocular hypertension and POAG are described. Expand
Morphologic characteristics of the human ciliary muscle
TLDR
The specific intracellular, membraneous, and extracellular components described in the literature are listed and supplemented with own observations to better understand its unique role in the concert of uveal smooth muscle cells. Expand
Research, Discovery and Development of Novel Therapeutics for the EyeDiseases Allergic Conjunctivitis and Glaucoma
This review article describes research conducted in the discovery and development of drugs to treat seasonal allergic conjunctivitis (SAC), ocular hypertension (OHT) and primary open-angle glauocmaExpand
Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies
TLDR
It is proposed that ROP should no longer be considered an inner retinal vasculopathy only, but also a disease of choroidal degeneration affecting both retinal pigment epithelium and photoreceptor integrity, and choroid degeneration as a significant cause of residual visual loss following ROP. Expand
Review of the mechanisms and therapeutic avenues for retinal and choroidal vascular dysfunctions in retinopathy of prematurity
TLDR
Observations regarding neurovascular dysfunctions in both the inner and outer immature retina, the mechanisms and the neuronal‐derived factors implicated in the development of ROP, as well potential therapeutic avenues for this disorder are focused on. Expand

References

SHOWING 1-10 OF 49 REFERENCES
Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology.
  • T. Davis, N. Sharif
  • Chemistry, Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 1999
TLDR
Quantitative autoradiographic visualization of FP prostaglandin receptors was determined in postmortem human eye sections using [3H]PGF2alpha and the novel phosphor-imaging technology coupled with computerized image analysis to provide further evidence for the presence of FP receptors in human longitudinal ciliary muscle, one of the tissues involved in the intraocular pressure lowering effects of FP-class prostaglandsins. Expand
Further studies on ocular responses to DP receptor stimulation.
TLDR
Findings reinforce the concept that selective DP receptor agonists may be useful for lowering intraocular pressure without causing ocular surface pathology and suggest a possible subdivision of the DP receptor designation. Expand
The DP‐Receptor Agonist SQ27986 Raises but Does Not Lower Intraocular Pressure in Ocular Normotensive Monkeys
TLDR
The inability of SQ27986 to reduce IOP in ocular normotensive monkeys suggests that DP-receptor stimulation does not increase uveoscleral outflow or play a major role in IOP reduction by other relatively nonselective prostaglandins such as PGF2α. Expand
The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.
TLDR
The results indicate that the dominant prostanoid receptor in the human ciliary muscle is the EP2 subclass and that there is also a small number of DP receptors. Expand
Selective prostaglandin D2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats.
TLDR
The results clearly show that the DP receptors in rabbit and cat eyes are involved in intraocular pressure regulation, however, under baseline conditions DP receptor activity does not contribute to this regulation. Expand
Studies on prostanoid receptors in ocular tissues.
TLDR
The work on PG binding sites in ocular tissues and PG receptors coupled to adenylyl cyclase or phosphoinositidase C signal transduction pathways in Ocular tissues of various animal species is reviewed. Expand
Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans
TLDR
The results indicate that although PGD2 and BW245C are effective in reducing human IOP, their clinical usefulness as anti-glaucoma drugs may be limited by the extraocular side effects. Expand
Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist.
TLDR
Clinical studies show that travoprost 0.004% (isopropyl ester) provided intraocular pressure control superior to timolol 0.5% when used as monotherapy in patients with open-angle glaucoma or ocular hypertension, and AL-6598 0.01% provided a sustained intraocular Pressure reduction with q.i.d. application. Expand
Prostaglandin derivates as ocular hypotensive agents
  • A. Alm
  • Medicine
  • Progress in Retinal and Eye Research
  • 1998
TLDR
The drug reaches systemic concentrations that are below the level expected to stimulate FP-receptors outside the eye and it is rapidly eliminated with a half-life in plasma of 17 minutes, which explains why the clinical trials have not revealed any systemic side-effects with latanoprost. Expand
Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye.
TLDR
The FP receptor was found to be distributed widely in the ocular tissues, suggesting an array of autocrine and paracrine functions of PGF2 alpha in the eye. Expand
...
1
2
3
4
5
...